Results 11 to 20 of about 99,253,553 (299)
Clinical Use of DPP-4 Inhibitors [PDF]
Frontiers in Endocrinology, 2019 DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
Baptist Gallwitz
exaly +5 more sources
Renoprotective Effects of DPP-4 Inhibitors [PDF]
Antioxidants, 2021 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins.
Yuichi Takashi +2 more
exaly +4 more sources
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine +8 more
doaj +2 more sources
A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. [PDF]
PLoS ONE, 2015 Myocarditis is a critical inflammatory disorder which causes life-threatening conditions. No specific or effective treatment has been established. DPP-4 inhibitors have salutary effects not only on type 2 diabetes but also on certain cardiovascular ...
Hiroyuki Hirakawa +7 more
doaj +2 more sources
DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. [PDF]
PLoS ONE, 2014 Diabetic nephropathy is a common causative factor of chronic kidney disease (CKD). DPP-4 inhibitor has the ability to improve kidney function and renal microvasculature.
Wei-Jie Wang +4 more
doaj +2 more sources
Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. [PDF]
Diabetes Metab Syndr Obes, 2023 Naoyuki Akashi,1 Tomio Umemoto,1 Hodaka Yamada,2 Takayuki Fujiwara,3 Kei Yamamoto,1 Yousuke Taniguchi,1 Kenichi Sakakura,1 Hiroshi Wada,1 Shin-ichi Momomura,1 Hideo Fujita1 1Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical ...
Akashi N +9 more
europepmc +2 more sources
Lipids in Health and Disease, 2017 Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes.
Seon-Ah Cha +7 more
doaj +2 more sources
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases [PDF]
BMC Nephrology, 2020 Background Dipeptidyl peptidase-4 (DPP-4) is a serine protease that inhibits the degradation of glucagon-like peptide 1. DPP-4 inhibitors are used worldwide to treat type 2 diabetes mellitus and were recently shown to have pleiotropic effects such as ...
Ayano Kubo +6 more
doaj +2 more sources
Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. [PDF]
J Pers Med, 2022 To determine the efficacy of glucose control in type 2 diabetes patients who switch from dipeptidyl peptidase-4 (DPP-4) inhibitors use or non-use to GLP-1 receptor agonists (GLP-1 RAs).
Tsai CJ, Tsao CF.
europepmc +2 more sources
Journal of Pharmacological Sciences, 2019 Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
Takehiro Yamaguchi +12 more
doaj +2 more sources